FDAnews
www.fdanews.com/articles/198998-appili-submits-protocol-for-phase-3-covid-19-trial-of-favipiravir-to-fda
Favipiravir, pill

Appili Submits Protocol for Phase 3 COVID-19 Trial of Favipiravir to FDA

September 14, 2020

Canadian drugmaker Appili Therapeutics said it has submitted a new protocol to the FDA for a phase 3 U.S. trial of its influenza antiviral favipiravir as an outpatient treatment for COVID-19.

The study will evaluate the drug’s safety and efficacy for treatment of mild-to-moderate COVID-19 and assess whether it can shorten recovery time and keep infections from progressing to more serious illness.

Appili plans to begin recruiting for the trial this fall. It aims to enroll 826 patients, who will either receive the drug or a placebo.

View today's stories